Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/2872
|
| Title: | Topoisomerase 2 alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia |
| Authors: | Liu, JM;Wang, LS;Huang, MH;Hsu, WH;Yen, SH;Shiau, CY;Li, AFY;Tiu, CM;Tseng, SW;Huang, BS |
| Contributors: | National Institute of Cancer Research |
| Abstract: | BACKGROUND. Microsatellite studies in histologic types B3 and C thymic neoplasia detected gains on chromosome 17q, which contains the Her-2/neu and its juxtaposed topoisomerase 2 alpha (T2 alpha) genes. The study aimed to evaluate their impact on tumor biology and survival of advanced thymic neoplasia patients. METHODS. From 1991 to 2005, 36 consecutive stage IV thymic carcinoma patients were treated, 18 men and 18 women, aged 11 to 84 years. There were 22 thymic carcinoma, 13 type 133, and 1 type B2 thymoma. Patients received treatment consisting of surgical resection, combination chemotherapy with the CAP (cyclophosphamide, Adriamycin, cisplatin) regimen, or radiation therapy potentiated by high-dose weekly 5-fluorouracil infusion. Permutations of these 3 treatment modalities were prescribed as necessary. RESULTS. T2 alpha gene amplification was detected in 4 of 14 thymic carcinoma and I of 15 type 133 thymoma. Three thymic carcinoma patients had Her-2/neu coamplification and these 3 patients had rapidly growing tumor and extensive disease at initial diagnosis. CAP was prescribed in 28 patients and 20 patients responded (response rate, 71.4%, 95% confidence interval [CI]: 52.8% to 85%); all responders overexpressed (>= 10% nuclei positive) the T2 alpha protein, whereas 4 nonresponders had very low expression. T2a overexpression predicts CAP response, and its absence predicts resistance (P = .001). Overall survival was significantly prolonged if the tumor was resectable (P = .001), of type 133 histology (P = .0039), and had no Her-2 gene amplification (P = .0081). CONCLUSIONS. T2 alpha and Her-2/neu genes play a pivotal role in the tumor biology, CAP response, and survival of advanced thymic neoplasia patients. |
| Keywords: | Oncology |
| Date: | 2007-02-01 |
| Relation: | Cancer. 2007 Feb;109(3):502-509. |
| Link to: | http://dx.doi.org/10.1002/cncr.22404 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0008-543X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000243869700006 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33846682699 |
| Appears in Collections: | [曾思文(1997-2007)] 期刊論文
[劉敏(1996-2007)] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 000243869700006.pdf | | 285Kb | Adobe PDF | 1571 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
